Proactive Investors - Run By Investors For Investors

Anavex Life Sciences advancing its Parkinson's disease therapy through the pipeline

Anavex Life Sciences Corp (NASDAQ:AVXL) President and CEO Christopher Missling sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biopharmaceutical company is developing therapeutics to treat neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system diseases, pain, and various types of cancer.

 
View full AVXL profile View Profile

Anavex Life Sciences Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use